Evaluación de la susceptibilidad a glicopéptidos en cepas de Staphylococcus aureus resistentes a oxacilina.
Saved in:
| Title: | Evaluación de la susceptibilidad a glicopéptidos en cepas de Staphylococcus aureus resistentes a oxacilina. |
|---|---|
| Alternate Title: | Evaluation of Susceptibility to Glycopeptides in Oxacillin Resistant Staphylococcus aureus Strains. |
| Authors: | González, Maribel Castellano1 maribeljo@cantv.net, Armindo, Perozo Mena2, González, Ana Isabel3 |
| Source: | Revista Kasmera. ene-jun2012, Vol. 40 Issue 1, p11-22. 12p. |
| Abstract (English): | The decrease in susceptibility to glycopeptides by oxacillin resistant Staphylococcus aureus (ORSA) has become a current problem. Objective: To evaluate susceptibility to glycopeptides in ORSA strains isolated in the University Hospital, Maracaibo, during the first quarter of 2010. Methods: Oxacillin resistance of the ORSA strains was verified by diffusion on agar (oxacillin 1 µg and cefoxitin 30 µg, OXOID®), a screening test in Müeller Hinton agar with 6 µg/mL of vancomycin (Sigma®), and E-test® for minimum inhibitory concentration (MIC) for oxacillin, detection of PBP2a (Latex, OXOID®) and the mecA gene by polymerase chain reaction (PCR). In addition, susceptibility to glycopeptides was determined by disk diffusion (teicoplanin, 30 µg OXOID®), MIC by E-test®, screening test in Müeller-Hinton agar with teicoplanin (5 µg/ml) or in brain heart infusion agar with vancomycin (6 µg/mL), glycopeptide hetero-resistance detection by GDR E-test® and detection of the vanA gene using PCR. Results: No ORSA strain was isolated with intermediate resistance (VISA or hVISA), nor with high-level resistance to glycopeptides. Conclusions: Locally, there is no incidence of ORSA strains resistant to glycopeptides; therefore, these antibiotics continue to be useful for treating infections produced by this important pathogen. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): | La disminución de la susceptibilidad a los glicopéptidos por parte de Staphylococcus aureus oxacilina resistente (SAOR) se ha convertido en una problemática actual. Objetivo: Evaluar la susceptibilidad a los glicopéptidos en cepas SAOR aisladas en el Hospital Universitario de Maracaibo, durante el primer trimestre del 2010. Métodos: a las cepas SAOR se les verificó la resistencia a oxacilina por difusión en agar (oxacilina 1 µg y cefoxitina 30 µg, OXOID®), prueba de descarte en agar Müeller Hinton con 6 µg/mL de oxacilina (Sigma®), concentración inhibitoria mínima (CIM) a oxacilina mediante E-test®, detección de PBP2a (látex, OXOID®) y del gen mecA por reacción en cadena de la polimerasa (PCR). Se determinó, además, la susceptibilidad a glicopéptidos por difusión del disco (teicoplanina 30 µg, OXOID®), CIM por E-test®, prueba de descarte en agar Müeller-Hinton con teicoplanina (5 µg/mL, Sigma®) o infusión cerebro corazón con vancomicina (6 µg/mL, Sigma ®), detección de hetero-resistencia (GDR E-test®) y la detección del gen vanA mediante PCR.Resultados: no se aisló ninguna cepa SAOR con resistencia intermedia (VISA o hVISA), ni tampoco, con resistencia de alto nivel a glicopéptidos (SAVR). Conclusiones: En la localidad, no existe incidencia de cepas SAOR resistentes a los glicopéptidos, por lo que estos antibióticos continúan siendo de utilidad en la terapéutica de las infecciones producidas por este importante patógeno. [ABSTRACT FROM AUTHOR] |
| Copyright of Revista Kasmera is the property of Revista Kasmera and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | MedicLatina |
Be the first to leave a comment!
